NextFin News - In a significant advancement for men’s health and precision oncology, a multi-institutional clinical trial has confirmed the efficacy of a novel laser focal therapy device, ProFocal, in treating localized prostate cancer. The study, published on January 28, 2026, in the journal BJU International, reveals that the pinpoint laser treatment successfully eliminated clinically significant cancer in 84% of participants while maintaining a safety profile far superior to traditional whole-gland interventions. Conducted by researchers from the University of Western Australia, the University of Sydney, and Nepean Hospital in New South Wales, the trial involved 100 patients and focused on the "Trifecta concept": achieving cancer cure, urinary continence, and sexual potency simultaneously.
The ProFocal system, developed by Medlogical Innovations under the leadership of Associate Professor Celi Varol, utilizes a cooled laser focal therapy device to ablate cancerous tissue with millimeter accuracy. Unlike radical prostatectomy or radiotherapy, which treat the entire prostate gland and often damage surrounding nerves, this focal approach uses ultrasound overlaid on MRI results to guide a needle-guided laser directly to the tumor. According to News-Medical, the trial results showed that only 12% of men reported erectile dysfunction post-treatment, and there was a negligible 4.5% decline in urinary function—figures that stand in stark contrast to the 30-50% morbidity rates often associated with traditional surgeries.
The emergence of ProFocal represents a critical shift in the urological treatment paradigm, moving away from "over-treatment" of low-to-intermediate grade cancers. For decades, the medical community has grappled with the dilemma of treating prostate cancer: while the disease is the most commonly diagnosed cancer in men—with over 26,000 cases in Australia alone in 2024—the side effects of curative treatment have often been as debilitating as the disease itself. By targeting only the lesion, ProFocal addresses the psychological and physiological barriers that prevent many men from seeking early diagnosis. U.S. President Trump’s administration has recently emphasized the importance of domestic medical innovation and streamlined FDA-equivalent pathways, a policy environment that mirrors the support Medlogical Innovations received from the New South Wales Medical Devices Fund to establish local manufacturing.
From a financial and healthcare systems perspective, the adoption of focal laser therapy could lead to substantial cost savings. Traditional prostate cancer treatments often require multi-day hospital stays and extensive post-operative rehabilitation for incontinence and sexual dysfunction. In contrast, the ProFocal procedure is completed in under an hour, often under mild sedation, allowing patients to return to normal activities the following day. This "office-based" potential reduces the burden on surgical theaters and hospital beds. Furthermore, as manufacturing scales in facilities like the one in Lane Cove, Sydney, the unit cost of single-use laser ablation sets is expected to decrease, making the technology a viable candidate for global export into the multi-billion dollar urological device market.
Looking ahead, the success of the ProFocal trial suggests a broader trend toward organ-sparing therapies in oncology. The precision delivery system used in this trial is already attracting interest for applications in lung and spinal oncology, where localized ablation of tumors could replace more invasive thoracic or orthopedic surgeries. However, long-term data remains the final hurdle; while the 3-month biopsy results are promising, the urological community will require 5-to-10-year follow-up data to ensure that focal therapy does not lead to higher rates of local recurrence compared to radical excision. If long-term efficacy is proven, focal laser therapy is poised to become the primary recommendation for Grade 2 and 3 prostate cancers, fundamentally altering the landscape of men's preventative health and surgical oncology by the end of the decade.
Explore more exclusive insights at nextfin.ai.
